Drug intelligence / Profile preview

GP01CR21

Development stage: Preclinical
Lead developer: Exicure
Modality: Small Molecules

Overview

GP01CR21 is a preclinical-stage small molecule therapeutic being developed by GPCR Therapeutics for the treatment of cancer. The compound is designed to target the C-X-C chemokine receptor type 4 (CXCR4) in conjunction with an undisclosed G protein-coupled receptor (GPCR). GPCR Therapeutics' development strategy centers on the biology of GPCR heteromers—complexes formed by two different GPCRs that exhibit unique signaling properties and physiological roles compared to their monomeric counterparts. By specifically targeting the CXCR4-GPCR heteromer, GP01CR21 aims to inhibit oncogenic signaling pathways more selectively and effectively than traditional CXCR4 antagonists, with the goal of suppressing tumor growth and metastasis.

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on GP01CR21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GP01CR21.

Explore the full profile